.jpeg)
2026-08-27 05:38:45
In August 2026, the FDA approved zanidatamab (Ziihera) in combination with tislelizumab and chemotherapy for HER2-positive advanced gastroesophageal adenocarcinoma, achieving a median OS of 26.4 months. This article details the clinical data, indications, safety warnings, and dosing guidelines.
2026-08-26 07:44:33
Acalabrutinib is a selective oral BTK inhibitor for B-cell malignancies like CLL. This article outlines its twice-daily dosing, the timeline for efficacy evaluation, and the importance of adherence.
2026-08-26 07:21:45
Osimertinib (brand name: TAGRISSO) is a third-generation EGFR tyrosine kinase inhibitor for EGFR-mutant NSCLC. This article reviews its clinical efficacy, food administration advice, tablet handling, and key safety precautions.
2026-08-26 07:14:21
Bosutinib is a BCR-ABL/SRC tyrosine kinase inhibitor primarily indicated for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This article reviews its established indications, investigational use in autosomal dominant polycystic kidney disease (ADPKD), and critical safety boundaries.
2026-08-26 07:10:57
Ceritinib (brand name: Zykadia) is a second-generation oral ALK tyrosine kinase inhibitor for ALK-positive non-small cell lung cancer. This guide outlines the recommended 450mg once-daily dosing with food, dose modification principles, and missed-dose protocols to support safe and effective treatment.
2026-08-26 07:08:08
Ruxolitinib is a JAK1/JAK2 inhibitor used in myelofibrosis and other myeloproliferative neoplasms. This guide outlines drug interactions involving CYP3A4/CYP2C9, dosing considerations in hepatic impairment, and safety precautions during infection.
2026-08-26 07:04:50
Revumenib (brand name: REVUFORJ) is a leading oral menin inhibitor designed for relapsed/refractory acute leukemias with KMT2A translocations or NPM1 mutations. This article explores its innovative mechanism of blocking aberrant protein interactions, correcting leukemogenic transcription programs, and outlines key clinical indications and safety management.
2026-08-26 07:02:04
Pretomanid is a novel anti-tuberculosis agent used in combination with bedaquiline and linezolid as the BPaL regimen for drug-resistant TB. This guide outlines the adverse effect profile of the combination, key safety monitoring points, and clinical management strategies to help clinicians and patients navigate treatment risks.
2026-08-25 08:20:48
Asciminib (brand name: Scemblix) is the world's first approved BCR-ABL1 allosteric inhibitor, offering a novel treatment option for chronic myeloid leukemia. This guide outlines its targeted mechanism of action, indication-specific dosing, missed-dose protocols, and key safety monitoring points.
2026-08-25 08:14:06
Vigabatrin (brand name: Sabril) is the first irreversible GABA transaminase inhibitor, holding a unique place in the treatment of infantile spasms and refractory complex partial seizures. This guide provides a comprehensive overview of its chemistry, mechanism, pharmacokinetics, dosing protocols, vision risk management, and drug interactions for clinicians and caregivers.
2026-08-25 08:10:21
Belzutifan (WELIREG) is a first-in-class oral HIF-2α inhibitor approved for VHL-associated renal cell carcinoma, CNS hemangioblastomas, and pancreatic neuroendocrine tumors. This guide outlines dosing, time to response, follow-up schedules, discontinuation criteria, and long-term management strategies for patients and clinicians.
2026-08-24 07:51:59
Lapatinib is an oral dual HER2/EGFR tyrosine kinase inhibitor. Key adverse effects to monitor during treatment include diarrhea, skin reactions, and hepatic function changes. This article outlines recognition points and graded management strategies.
